Cross-sectional evaluation reveals fetuin-A and lipid profiles as key risk indicators in subclinical hypothyroidism, suggesting targeted management.
Objectives: To evaluate Fetuin-A (FA) as an integrative biomarker for cardiometabolic risk in subclinical hypothyroidism (SCH) and to investigate lipid-based metabolic heterogeneity. Methods: In this cross-sectional study, 192 participants (105 SCH, 87 controls) were evaluated for thyroid function, metabolic parameters, lipid profiles, FA, and high-sensitivity C-reactive protein (hs-CRP). Lipid phenotyping was performed using principal component analysis (PCA) and latent profile analysis (LPA). A composite cardiovascular disease risk index (CVDRI) incorporating FA and the atherogenic index of plasma (AIP), was calculated. Correlation, regression, and receiver operating characteristic (ROC) analysis were conducted. Results: SCH patients exhibited significantly elevated TSH, insulin resistance, dyslipidemia, hs-CRP, and FA compared to controls (p<0.0001). FA showed strong correlation with TSH, lipid parameters, insulin resistance, and CVDRI (ρ=0.60-0.77, p<0.001). PCA and LPA identified three distinct SCH phenotypes with progressively adverse metabolic and inflammatory profiles. ROC analysis demonstrated excellent discriminatory performance of FA and CVDRI (AUC > 95%), while lipid-derived indices differentiated high-risk phenotypes. Conclusion: FA is a promising integrative biomarker linking thyroid dysfunction with cardiometabolic risk in SCH. Lipid-based phenotyping highlights disease heterogeneity and supports the use of composite biomarker strategies for early risk stratification and personalized management.
No takes yet. Share an insight, caveat, or question.
Abdallah et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: